AIM ImmunoTech CEO Thomas K Equels acquires common shares worth $4,992
Thomas K. Equels, CEO, President, director, bought 24,000 AIM ImmunoTech common shares at $0.21 each. Direct holdings rose to 126,822 shares following the purchase. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and